• SPX
  • $5,712.69
  • -0.28 %
  • -$16.11
  • DJI
  • $41,794.60
  • -0.61 %
  • -$257.59
  • N225
  • $38,053.67
  • -2.63 %
  • -$1,027.58
  • FTSE
  • $8,184.24
  • 0.09 %
  • $7.09
  • IXIC
  • $18,179.98
  • -0.33 %
  • -$59.93
Recursion Pharmaceuticals, Inc. (RXRX) Stock Price, News & Analysis

Recursion Pharmaceuticals, Inc. (RXRX) Stock Price, News & Analysis

Currency in USD Disclaimer

$6.63

$0.23

(3.59%)

Day's range
$6.22
Day's range
$6.69
50-day range
$5.89
Day's range
$8.16
  • Country: US
  • ISIN: US75629V1044
52 wk range
$5.04
Day's range
$15.74
  • CEO: Dr. Christopher C. Gibson Ph.D.
  • Website: Visit Site


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score 2.80
  • Piotroski Score 3.00
  • Grade Buy
  • Symbol (RXRX)
  • Company Recursion Pharmaceuticals, Inc.
  • Price $6.63
  • Changes Percentage (3.59%)
  • Change $0.23
  • Day Low $6.22
  • Day High $6.69
  • Year High $15.74

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 11/06/2024
  • Fiscal Year End N/A

  • Average Stock Price Target $11.00
  • High Stock Price Target $12.00
  • Low Stock Price Target $6.00
  • Potential Upside/Downside N/A
  • Consensus Rating Strong Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$1.63
  • Trailing P/E Ratio -5.22
  • Forward P/E Ratio -5.22
  • P/E Growth -5.22
  • Net Income $-328,066,000

Income Statement

Quarterly

Annual

Latest News of RXRX

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.